Zhejiang Xianju Pharmaceutical Co.,Ltd.

XSEC:002332 Stock Report

Market Cap: CN¥10.0b

Zhejiang Xianju PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Zhejiang Xianju PharmaceuticalLtd has been growing earnings at an average annual rate of 9.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.4% per year. Zhejiang Xianju PharmaceuticalLtd's return on equity is 10.4%, and it has net margins of 15.1%.

Key information

9.1%

Earnings growth rate

7.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate2.4%
Return on equity10.4%
Net Margin15.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Xianju PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:002332 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,1236221,258306
30 Jun 244,1436011,286293
31 Mar 244,2045811,307288
31 Dec 234,1235631,264261
30 Sep 234,1646921,289255
30 Jun 234,2707201,362263
31 Mar 234,2887551,443251
01 Jan 234,3807491,536267
30 Sep 224,4936891,571237
30 Jun 224,4426761,597241
31 Mar 224,4056361,588249
01 Jan 224,3576191,560243
30 Sep 214,4026051,478232
30 Jun 214,3915731,472232
31 Mar 214,2765481,418232
31 Dec 204,0195051,335208
30 Sep 203,8734781,381228
30 Jun 203,6204421,307215
31 Mar 203,6184201,363210
31 Dec 193,7094101,430205
30 Sep 193,7413811,503169
30 Jun 193,7233521,497161
31 Mar 193,6283191,483146
31 Dec 183,6223011,474143
30 Sep 183,5142771,421124
30 Jun 183,3372491,313135
31 Mar 183,1162311,227107
31 Dec 172,8532071,13388
30 Sep 172,6711871,08847
30 Jun 172,5721681,0960
31 Mar 172,5471491,0890
31 Dec 162,5041461,0450
30 Sep 162,4571359620
30 Jun 162,5041239450
31 Mar 162,4411089000
31 Dec 152,4801078770
30 Sep 152,466888460
30 Jun 152,461718510
31 Mar 152,473608260
31 Dec 142,471577960
30 Sep 142,408458090
30 Jun 142,370387270
31 Mar 142,373516710
31 Dec 132,315616550

Quality Earnings: 002332 has high quality earnings.

Growing Profit Margin: 002332's current net profit margins (15.1%) are lower than last year (16.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002332's earnings have grown by 9.1% per year over the past 5 years.

Accelerating Growth: 002332's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002332 had negative earnings growth (-10.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 002332's Return on Equity (10.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 04:03
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Xianju Pharmaceutical Co.,Ltd. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Pei ChengChina Galaxy Securities Co., Ltd.
Feifei XuChina Merchants Securities Co. Ltd.